Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Merck KGAA forms IBS spin-out Tioga Pharmaceuticals

Executive Summary

Merck KGAA has spun out Tioga Pharmaceuticals, a new company formed to further develop Merck's asimadoline for irritable bowel syndrome (IBS). Tioga raised an undisclosed amount in its Series A financing (including an investment by Forward Ventures), and is already planning to raise additional funds.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Spin-Off
    • Private Placement

Related Companies

Advertisement
UsernamePublicRestriction

Register